AUTHOR=Peña-Flores José A. , Bermúdez Mercedes , Ramos-Payán Rosalío , Villegas-Mercado Carlos E. , Soto-Barreras Uriel , Muela-Campos Daniela , Álvarez-Ramírez Alexis , Pérez-Aguirre Brenda , Larrinua-Pacheco Ana D. , López-Camarillo César , López-Gutiérrez Jorge A. , Garnica-Palazuelos Julio , Estrada-Macías Marvin E. , Cota-Quintero Juan L. , Barraza-Gómez Andrés A. TITLE=Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma JOURNAL=Frontiers in Oncology VOLUME=12 YEAR=2022 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.965628 DOI=10.3389/fonc.2022.965628 ISSN=2234-943X ABSTRACT=

Head and neck squamous cell carcinoma (HNSCC) originates in the squamous cell lining the mucosal surfaces of the head and neck region, including the oral cavity, nasopharynx, tonsils, oropharynx, larynx, and hypopharynx. The heterogeneity, anatomical, and functional characteristics of the patient make the HNSCC a complex and difficult-to-treat disease, leading to a poor survival rate and a decreased quality of life due to the loss of important physiologic functions and aggressive surgical injury. Alteration of driver-oncogenic and tumor-suppressing lncRNAs has recently been recently in HNSCC to obtain possible biomarkers for diagnostic, prognostic, and therapeutic approaches. This review provides current knowledge about the implication of lncRNAs in drug resistance mechanisms in HNSCC. Chemotherapy resistance is a major therapeutic challenge in HNSCC in which lncRNAs are implicated. Lately, it has been shown that lncRNAs involved in autophagy induced by chemotherapy and epithelial–mesenchymal transition (EMT) can act as mechanisms of resistance to anticancer drugs. Conversely, lncRNAs involved in mesenchymal–epithelial transition (MET) are related to chemosensitivity and inhibition of invasiveness of drug-resistant cells. In this regard, long non-coding RNAs (lncRNAs) play a pivotal role in both processes and are important for cancer detection, progression, diagnosis, therapy response, and prognostic values. As the involvement of more lncRNAs is elucidated in chemoresistance mechanisms, an improvement in diagnostic and prognostic tools could promote an advance in targeted and specific therapies in precision oncology.